New Delhi-based Mankind Pharma has submitted its first Investigational New Drug (IND) application for approval to the Indian Drug Regulatory Authority, Central Drugs Standard Control Organisation (CDSCO) for MKP10241, a patented first in Class Novel Anti Diabetic Molecule.

The company has worked relentlessly in developing this new class of anti-diabetic molecules- designed and developed at the Mankind Research Centre. MKP10241 is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroendocrine cells.

With subsequent approval by CDSCO and the launch of this first in class drug, the company strongly anticipates that it will be of immense benefit to diabetic patients, and will prove to be extremely effective in lowering blood sugar levels.

What makes MKP10241 unique is its mechanism of action. GPR119 elevates intracellular secondary messengers such as cAMP inside the cells and promotes postprandial insulin and incretin secretion (GLP-1) in a glucose-dependent manner. This dual mechanism by GPR119 in mediating glucose-dependent insulin secretion is distinct from the currently available therapeutic options for Type 2 diabetes and thus becomes a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.

RC Juneja, Executive Chairman, Mankind Pharma said, "Our team of scientists have worked tirelessly & with immense passion to develop this novel drug to benefit the people, and it will be affordable for patients. Mankind Pharma is committed to expanding its portfolio of products in the Indian market in all major therapeutic areas for the benefit of patients, prescribers and the healthcare system.”